Insta
Supreme Court of India (Sonu Mehta/Hindustan Times via Getty Images)
The Central government in its submissions before the Supreme Court has defended the vaccine pricing mechanisms employed by Covid-19 vaccine manufacturers by stating that both Bharat Biotech and Serum Institute of India have taken a financial risk in manufacturing vaccines, thus it is prudent to take a decision on pricing via negotiations and save statutory provisions as a last resort, Live Law has reported.
"Centre says both vaccine manufactures (SII & Bharat Biotech) have taken financial risk in manufacturing vaccines. So, it is prudent to take decisions on pricing through negotiations, keeping statutory provisions as a last resort.", the centre has submitted before the apex court.
The centre adds that the pricing factor of the vaccines will not have an impact on the beneficiaries as all the states have declared their intent to inoculate beneficiaries free of cost.
The centre has also argued that the current vaccination policy is based on expert advise and deliberations at the highest executive level and no interference is called for in a judicial proceeding.
"No interference by this Hon’ble Court as while dealing with a pandemic of this magnitude, the Executive does have a room for free play in the joints, in larger public interest", the affidavit states.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest